Fulcrum Therapeutics Inc. (FULC)
3.44
-0.25 (6.78%)
Upcoming Events
Latest Headlines
Form 8-K Fulcrum Therapeutics, For: May 31
June 4, 2026 4:05 PM - SEC Filing
Goldman Sachs Drop Coverage of Fulcrum Therapeutics Inc. (FULC)
June 2, 2026 4:26 PM - StreetInsider
JPMorgan Double Downgrades Fulcrum Therapeutics (FULC) to Underweight
June 2, 2026 4:26 PM - StreetInsider
Fulcrum plummets over 50% after scrapping lead sickle-cell drug on FDA concerns
June 2, 2026 6:42 AM - StreetInsider
H.C. Wainwright Downgrades Fulcrum Therapeutics (FULC) to Neutral
June 2, 2026 6:07 AM - StreetInsider
Leerink Downgrades Fulcrum Therapeutics (FULC) to Market Perform
June 2, 2026 6:03 AM - StreetInsider
Piper Sandler Double Downgrades Fulcrum Therapeutics (FULC) to Underweight
June 2, 2026 1:08 AM - StreetInsider
Truist Securities Downgrades Fulcrum Therapeutics (FULC) to Hold
June 2, 2026 1:04 AM - StreetInsider
Stifel Downgrades Fulcrum Therapeutics (FULC) to Hold
June 1, 2026 6:37 PM - StreetInsider
After-Hours Stock Movers: HPE, CRDO, FULC, ABVX, MCHP
June 1, 2026 4:37 PM - StreetInsider
Fulcrum Therapeutics discontinues pociredir program, begins strategic review
June 1, 2026 4:10 PM - StreetInsider
Form 8-K Fulcrum Therapeutics, For: Jun 01
June 1, 2026 4:07 PM - SEC Filing
Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review
June 1, 2026 4:05 PM - StreetInsider
Form SCHEDULE 13G/A Fulcrum Therapeutics, Filed by: Nantahala Capital Management, LLC
May 15, 2026 4:43 PM - SEC Filing
Form SCHEDULE 13G/A Fulcrum Therapeutics, Filed by: TCG Crossover GP II, LLC
May 15, 2026 4:33 PM - SEC Filing
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 8, 2026 4:30 PM - StreetInsider
Form 4 Fulcrum Therapeutics, For: Apr 23 Filed by: Lehrer-Graiwer Joshua
May 1, 2026 4:16 PM - SEC Filing
Form 3 Fulcrum Therapeutics, For: Apr 23 Filed by: Lehrer-Graiwer Joshua
May 1, 2026 4:10 PM - SEC Filing
Form DEFA14A Fulcrum Therapeutics,
April 30, 2026 4:20 PM - SEC Filing
Form ARS Fulcrum Therapeutics, For: Dec 31
April 30, 2026 4:17 PM - SEC Filing
Form DEF 14A Fulcrum Therapeutics, For: Jun 24
April 30, 2026 4:12 PM - SEC Filing
Form 10-Q Fulcrum Therapeutics, For: Mar 31
April 27, 2026 7:11 AM - SEC Filing
Fulcrum Therapeutics Inc. (FULC) Tops Q1 EPS by 5c
April 27, 2026 7:07 AM - StreetInsider
Form 8-K Fulcrum Therapeutics, For: Apr 23
April 27, 2026 7:05 AM - SEC Filing
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026
April 27, 2026 7:00 AM - Globe NewsWire
Fulcrum Therapeutics adds Josh Lehrer to board of directors
April 27, 2026 6:55 AM - StreetInsider
Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors
April 27, 2026 6:55 AM - Globe NewsWire
Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ET
April 20, 2026 8:00 AM - Globe NewsWire
Leerink on Fulcrum Therapeutics (FULC): 'We believe this is a positive sign for FULC'
March 31, 2026 1:08 PM - StreetInsider
Stifel: 'we think FULC as a soon-to-be ph3 SCD company is significantly under-appreciated'
March 31, 2026 8:54 AM - StreetInsider
Form SCHEDULE 13G/A Fulcrum Therapeutics, Filed by: VANGUARD GROUP INC
March 26, 2026 6:38 PM - SEC Filing
MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Livi
March 19, 2026 8:00 AM - StreetInsider
Full Article List
